US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Coya Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces $11.1 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Proposed Public Offering of Common Stock
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
News headline image
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
From Coya Therapeutics, Inc.
Via Business Wire
Tickers COYA
< Previous 1 2 3 4 Next >